Key facts
- Desentum’s last known valuation is $55.2M (Jan 2022).
- It has raised $48.6M; the latest was Later Stage VC ($9.4M) in Mar 2026.
- Notable investors include VTT Technical Research Centre of Finland, Cascara Ventures, Horizon 2020, STO-Rahoitus, Springvest — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Desentum
- ·The full record, as it builds
Funding rounds
No funding rounds for Desentum are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Desentum
Developer of a biopharmaceutical platform designed to create novel types of allergen immunotherapy products to fight allergies. The company's platform offers recombinant allergens that can be modified to suppress the histamine release during the desensitization process to safely and effectively treat allergies by reprogramming the immune system's response, enabling healthcare providers to significantly reduce the risk of adverse effects and the time required to treat allergies.
- Sector
- Healthcare
- HQ
- Espoo, Finland
- Founded
- 2011
- Employees
- 10
- Website
- desentum.fi/
- Ownership
- Privately Held (backing)
Desentum doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Desentum shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Desentum in its N-PORT filings yet. We sweep new filings monthly.